Resident and CEO, Interface Biologics
Tom Reeves is President and Chief Executive Officer of Interface Biologics (IBI) – a privately held commercial stage company that develops transformative bio-medical polymer technology to improve the safety and effectiveness of a broad range of medical devices. Tom is also on the Board of Directors for both Medcan and Soricimed Biopharma and was a finalist for the 2014 Ernst & Young Entrepreneur of the Year in Health Sciences. Prior to IBI, Tom was President and Chief Operating Office of Occulogix, Inc., a publicly traded medical device company focused on treatments for age-related eye diseases. He was instrumental in the company’s 2004 IPO, which raised $100M on a $500M valuation. Prior to OccuLogix, Tom was President and CEO of Borderfree, Ltd., a venture-backed international e-commerce service provider which was sold to Canada Post. Tom also spent 14 years in the computer products industry managing wholesale distribution companies in Canada, Europe and the UK. He began his career at the Boston Consulting Group in San Francisco and has degrees in economics and international relations from Harvard University and the Australian National University.